SCHEMBL6602286

SCHEMBL6602286

CCOc1c(F)c(-c2cccc(C)c2)nn1CCOc1ccc(-c2ccc(OC)cc2)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.37
L3MBTL1 Q9Y468 5/20 0.37
RAB9A P51151 4/20 0.37
ATM Q13315 1/20 0.37
HPGD P15428 7/20 0.37
TUBB4A P04350 2/20 0.36
TUBB P07437 2/20 0.36
TUBA3C P0DPH7 2/20 0.36
TUBA1B P68363 2/20 0.36
TUBA4A P68366 2/20 0.36
TUBB4B P68371 2/20 0.36
TUBB3 Q13509 2/20 0.36
TUBB2A Q13885 2/20 0.36
TUBB8 Q3ZCM7 2/20 0.36
TUBA3E Q6PEY2 2/20 0.36
TUBA1A Q71U36 2/20 0.36
TUBA1C Q9BQE3 2/20 0.36
TUBB6 Q9BUF5 2/20 0.36
TUBB2B Q9BVA1 2/20 0.36
TUBB1 Q9H4B7 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805266 0.93 CACNA2D1 (0.39) MAPTL3MBTL1RAB9AHPGDTUBB4A
SCHEMBL6601580 0.93 L3MBTL1 (0.42) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL6809966 0.92 HPGD (0.39) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL6799808 0.91 CACNA2D1 (0.38) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL6618518 0.89 MAPT (0.38) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL6604793 0.89 MAPT (0.36) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL6804443 0.89 MAPT (0.38) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL6601526 0.88 HPGD (0.40) MAPTL3MBTL1RAB9AATMHPGD
SCHEMBL6601576 0.87 CACNA2D1 (0.37) MAPTL3MBTL1HPGDTUBB4ATUBB
SCHEMBL6801273 0.87 L3MBTL1 (0.40) MAPTL3MBTL1RAB9AATMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 MAPT 3013/4885L3MBTL1 3508/4885RAB9A 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.